SEATTLE--(BUSINESS WIRE)--Jul. 7, 2016--
Omeros Corporation (NASDAQ:OMER), a biopharmaceutical company committed
to discovering, developing and commercializing both small-molecule and
protein therapeutics for large-market as well as orphan indications
targeting inflammation, coagulopathies and disorders of the central
nervous system, today announced that Gregory A. Demopulos, M.D.,
chairman and chief executive officer, will present at the Cantor
Fitzgerald 2nd Annual Healthcare Conference in New York next
week. The presentation is scheduled for Tuesday, July 12, 2016 at 10:45
a.m. EDT.
The presentation will be webcast. The live and archived webcasts can be
accessed on the “Events” page of the company’s website at www.omeros.com.
About Omeros Corporation
Omeros is a biopharmaceutical company committed to discovering,
developing and commercializing both small-molecule and protein
therapeutics for large-market as well as orphan indications targeting
inflammation, coagulopathies and disorders of the central nervous
system. Derived from its proprietary PharmacoSurgery® platform,
the company’s first drug product, OMIDRIA® (phenylephrine and
ketorolac injection) 1%/0.3%, was broadly launched in the U.S. in April
2015 for use during cataract surgery or intraocular lens (IOL)
replacement to maintain pupil size by preventing intraoperative miosis
(pupil constriction) and to reduce postoperative ocular pain. In
the European Union, the European Commission has approved OMIDRIA for use
in cataract surgery and lens replacement procedures to maintain
mydriasis (pupil dilation), prevent miosis (pupil constriction), and to
reduce postoperative eye pain. Omeros has five clinical-stage
development programs focused on: complement-related thrombotic
microangiopathies; complement-mediated glomerulopathies; Huntington’s
disease and cognitive impairment; addictive and compulsive disorders;
and preventing problems associated with urologic surgical procedures. In
addition, Omeros has a proprietary GPCR platform, which is making
available an unprecedented number of new GPCR drug targets and
corresponding compounds to the pharmaceutical industry for drug
development, and a platform used to generate antibodies.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160707005181/en/
Source: Omeros Corporation
Cook Williams Communications, Inc.
Jennifer Cook Williams,
360-668-3701
jennifer@cwcomm.org
